NEW YORK – DNAnexus said Tuesday that it has closed a new financing round worth $200 million. Blackstone Growth led the round, with participation from earlier investors Northpond Ventures, GV, Perceptive Advisors, Innovatus Capital Partners, and Foresite Capital.
The Mountain View, California-based bioinformatics company did not name the round, though this is the second time DNAnexus has landed a large investment since its Series F in 2019. The firm also completed a $100 million financing round in 2020.
DNAnexus said it would use the new money to refine its core genomics and multiomics technology platform, integrate new artificial intelligence and machine learning tools, and continue its international growth. The company has more than 12,000 users in 48 countries to date and counts the UK Biobank and the US Food and Drug Administration among its customers.
"The funding enables us to accelerate our product roadmap to meet the global demand for technologies harnessing the power of biomedical data and driving precision medicine forward," DNAnexus CEO Richard Daly said in a statement. "Blackstone will be a strong partner as we grow our business and support the new wave of biomedical insights generated by our customers using large-scale clinical, multiomics data."
"As a variety of healthcare constituents, including pharma, diagnostics businesses, and the FDA, increasingly leverage multiomic and clinical data for more accurate detection of disease and the development of precision medicines, we believe DNAnexus will continue to serve as the engine that helps power those important scientific developments and insights," said Mike Kirkman, head of healthcare for Blackstone Growth.